SCHEMBL3090417

SCHEMBL3090417

CCN(C(=O)C(Cc1ccc(OC)c(OC)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 9/20 0.45
LDHA P00338 1/20 0.44
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 2/20 0.42
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
THRB P10828 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090420 1.00 MMP1 (0.45) MMP1LDHAKDM4ELMNAMAPT
SCHEMBL15000154 0.90 MMP1 (0.47) MMP1LDHAKDM4ELMNAMAPT
SCHEMBL15000152 0.90 MMP1 (0.47) MMP1LDHAKDM4ELMNAMAPT
SCHEMBL3092141 0.89 PKM (0.38) MMP1LMNAMAPTPKMHTT
SCHEMBL3089116 0.89 ALDH1A1 (0.42) LMNAMAPTPKMHTTALDH1A1
SCHEMBL3089113 0.89 ALDH1A1 (0.42) LMNAMAPTPKMHTTALDH1A1
SCHEMBL3092146 0.89 PKM (0.38) MMP1LMNAMAPTPKMHTT
SCHEMBL3092630 0.89 ALDH1A1 (0.46) MMP1LDHALMNAHTTALDH1A1
SCHEMBL3092640 0.89 ALDH1A1 (0.46) MMP1LDHALMNAHTTALDH1A1
SCHEMBL3100032 0.87 ALDH1A1 (0.43) MMP1LDHALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MMP1 1303/4885LDHA 723/4885KDM4E 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.